CY1122587T1 - 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης - Google Patents
1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασηςInfo
- Publication number
- CY1122587T1 CY1122587T1 CY20191101079T CY191101079T CY1122587T1 CY 1122587 T1 CY1122587 T1 CY 1122587T1 CY 20191101079 T CY20191101079 T CY 20191101079T CY 191101079 T CY191101079 T CY 191101079T CY 1122587 T1 CY1122587 T1 CY 1122587T1
- Authority
- CY
- Cyprus
- Prior art keywords
- thioxo
- pyrimidin
- aminomethyl
- tetrahydro
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Αποκαλύπτονται ορισμένες ενώσεις 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4Η-πυρρολο[3,2-d]πυριμιδιν-4-όνης του τύπου (I), και φαρμακευτικά αποδεκτά άλατα αυτών, μαζί με συνθέσεις που τις περιέχουν και τη χρήση τους σε θεραπεία. Οι ενώσεις είναι αναστολείς του ενζύμου ΜΡΟ και είναι κατ' αυτόν τον τρόπο χρήσιμες στην αγωγή ή την προφύλαξη καρδιαγγειακών νόσων, όπως καρδιακή ανεπάρκεια και καταστάσεις που σχετίζονται με την στεφανιαία καρδιακή νόσο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462085722P | 2014-12-01 | 2014-12-01 | |
| US201562166808P | 2015-05-27 | 2015-05-27 | |
| PCT/EP2015/077998 WO2016087338A1 (en) | 2014-12-01 | 2015-11-30 | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122587T1 true CY1122587T1 (el) | 2021-01-27 |
Family
ID=54754631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101079T CY1122587T1 (el) | 2014-12-01 | 2019-10-15 | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US9616063B2 (el) |
| EP (1) | EP3227294B1 (el) |
| JP (1) | JP6616417B2 (el) |
| KR (1) | KR102543404B1 (el) |
| CN (1) | CN107001374B (el) |
| AU (1) | AU2015357290B2 (el) |
| BR (1) | BR112017011124B1 (el) |
| CA (1) | CA2968449C (el) |
| CL (1) | CL2017001380A1 (el) |
| CO (1) | CO2017006658A2 (el) |
| CY (1) | CY1122587T1 (el) |
| DK (1) | DK3227294T3 (el) |
| DO (1) | DOP2017000129A (el) |
| EA (1) | EA030805B1 (el) |
| ES (1) | ES2751690T3 (el) |
| GT (1) | GT201700114A (el) |
| HK (1) | HK1245270A1 (el) |
| HR (1) | HRP20191744T1 (el) |
| HU (1) | HUE045606T2 (el) |
| IL (1) | IL252436B (el) |
| LT (1) | LT3227294T (el) |
| ME (1) | ME03568B (el) |
| MX (1) | MX370492B (el) |
| MY (1) | MY195816A (el) |
| NI (1) | NI201700065A (el) |
| NZ (1) | NZ732164A (el) |
| PE (1) | PE20170914A1 (el) |
| PH (1) | PH12017500977A1 (el) |
| PL (1) | PL3227294T3 (el) |
| PT (1) | PT3227294T (el) |
| RS (1) | RS59375B1 (el) |
| SG (1) | SG11201703961UA (el) |
| SI (1) | SI3227294T1 (el) |
| SV (1) | SV2017005451A (el) |
| TN (1) | TN2017000208A1 (el) |
| TW (1) | TWI681963B (el) |
| UY (1) | UY36416A (el) |
| WO (1) | WO2016087338A1 (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9616063B2 (en) * | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
| JP7220193B2 (ja) * | 2017-07-17 | 2023-02-09 | アストラゼネカ・アクチエボラーグ | 医学における使用のためのｍｐｏ阻害剤 |
| CN112151111B (zh) * | 2020-08-27 | 2022-10-11 | 上海大学 | 基于多元线性回归快速预测黄嘌呤衍生物抑制活性的qsar方法 |
| CN115403584B (zh) * | 2021-05-26 | 2024-04-02 | 长春金赛药业有限责任公司 | 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用 |
| US20240166642A1 (en) | 2022-08-18 | 2024-05-23 | Astrazeneca Ab | Inhibitors of myeloperoxidase |
| US20240092787A1 (en) | 2022-08-24 | 2024-03-21 | Astrazeneca Ab | Pharmaceutical process and intermediates |
| WO2024047094A1 (en) | 2022-08-31 | 2024-03-07 | Astrazeneca Ab | Pharmaceutical formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| US20050130983A1 (en) * | 2002-05-02 | 2005-06-16 | Dae-Kee Kim | Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them |
| SE0302756D0 (sv) | 2003-10-17 | 2003-10-17 | Astrazeneca Ab | Novel Compounds |
| GB0401269D0 (en) * | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| ATE501148T1 (de) * | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| UY30267A1 (es) | 2006-04-13 | 2007-11-30 | Astrazeneca Ab | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones |
| JP2009533426A (ja) | 2006-04-13 | 2009-09-17 | アストラゼネカ・アクチエボラーグ | チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途 |
| WO2007142577A1 (en) | 2006-06-05 | 2007-12-13 | Astrazeneca Ab | Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
| AP2014007621A0 (en) | 2011-11-11 | 2014-05-31 | Pfizer | 2-Thiopyrimidinones |
| US9616063B2 (en) * | 2014-12-01 | 2017-04-11 | Astrazeneca Ab | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase |
-
2015
- 2015-11-25 US US14/951,979 patent/US9616063B2/en active Active
- 2015-11-30 LT LT15802075T patent/LT3227294T/lt unknown
- 2015-11-30 KR KR1020177016607A patent/KR102543404B1/ko active IP Right Grant
- 2015-11-30 ES ES15802075T patent/ES2751690T3/es active Active
- 2015-11-30 EA EA201791021A patent/EA030805B1/ru not_active IP Right Cessation
- 2015-11-30 PT PT158020750T patent/PT3227294T/pt unknown
- 2015-11-30 MX MX2017007322A patent/MX370492B/es active IP Right Grant
- 2015-11-30 CN CN201580065064.2A patent/CN107001374B/zh active Active
- 2015-11-30 CA CA2968449A patent/CA2968449C/en active Active
- 2015-11-30 ME MEP-2019-286A patent/ME03568B/me unknown
- 2015-11-30 NZ NZ732164A patent/NZ732164A/en unknown
- 2015-11-30 SI SI201530918T patent/SI3227294T1/sl unknown
- 2015-11-30 EP EP15802075.0A patent/EP3227294B1/en active Active
- 2015-11-30 UY UY0001036416A patent/UY36416A/es not_active Application Discontinuation
- 2015-11-30 WO PCT/EP2015/077998 patent/WO2016087338A1/en active Application Filing
- 2015-11-30 PL PL15802075T patent/PL3227294T3/pl unknown
- 2015-11-30 SG SG11201703961UA patent/SG11201703961UA/en unknown
- 2015-11-30 HU HUE15802075A patent/HUE045606T2/hu unknown
- 2015-11-30 TN TN2017000208A patent/TN2017000208A1/en unknown
- 2015-11-30 RS RSP20191310 patent/RS59375B1/sr unknown
- 2015-11-30 MY MYPI2017701958A patent/MY195816A/en unknown
- 2015-11-30 JP JP2017528830A patent/JP6616417B2/ja active Active
- 2015-11-30 TW TW104139983A patent/TWI681963B/zh active
- 2015-11-30 BR BR112017011124-1A patent/BR112017011124B1/pt active IP Right Grant
- 2015-11-30 PE PE2017000940A patent/PE20170914A1/es unknown
- 2015-11-30 AU AU2015357290A patent/AU2015357290B2/en active Active
- 2015-11-30 DK DK15802075.0T patent/DK3227294T3/da active
-
2017
- 2017-03-09 US US15/454,318 patent/US10016430B2/en active Active
- 2017-05-22 IL IL252436A patent/IL252436B/en active IP Right Grant
- 2017-05-26 PH PH12017500977A patent/PH12017500977A1/en unknown
- 2017-05-30 CL CL2017001380A patent/CL2017001380A1/es unknown
- 2017-05-30 DO DO2017000129A patent/DOP2017000129A/es unknown
- 2017-05-31 SV SV2017005451A patent/SV2017005451A/es unknown
- 2017-06-01 GT GT201700114A patent/GT201700114A/es unknown
- 2017-06-01 NI NI201700065A patent/NI201700065A/es unknown
- 2017-06-30 CO CONC2017/0006658A patent/CO2017006658A2/es unknown
-
2018
- 2018-04-12 HK HK18104749.6A patent/HK1245270A1/zh unknown
- 2018-06-15 US US16/009,590 patent/US11000525B2/en active Active
-
2019
- 2019-09-26 HR HRP20191744TT patent/HRP20191744T1/hr unknown
- 2019-10-15 CY CY20191101079T patent/CY1122587T1/el unknown
-
2021
- 2021-04-12 US US17/228,492 patent/US11975004B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122587T1 (el) | 1-[2-(αμινομεθυλο)βενζυλο]-2-θειοξο-1,2,3,5-τετραϋδρο-4η-πυρρολο[3,2-d]πυριμιδιν-4-ονες ως αναστολεις της μυελοϋπεροξειδασης | |
| CY1121433T1 (el) | Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4 | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1122703T1 (el) | 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων | |
| CY1120941T1 (el) | Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| BR112017009671A2 (pt) | inibidores de ezh2 e usos destes | |
| PH12019501261A1 (en) | Heterocyclic inhibitors of mct4 | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CY1124751T1 (el) | Συνδυαστικες αγωγες οι οποιες περιλαμβανουν χορηγηση 1η-πυραζολο[4,3-b]πυριδινων | |
| CY1120700T1 (el) | Ενωσεις τριαμινοπυριμιδινης χρησιμες για προληψη ή αγωγη ελονοσιας | |
| CY1121909T1 (el) | Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| CR20170229A (es) | 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d] pirimidin-4-onas como inhibidores de mieloperoxidasa |